Stay updated on Pembrolizumab+Radiotherapy in Metastatic TNBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Radiotherapy in Metastatic TNBC Clinical Trial page.

Latest updates to the Pembrolizumab+Radiotherapy in Metastatic TNBC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe ClinicalTrials.gov page now displays the completed study record for pembrolizumab plus radiotherapy in metastatic triple-negative breast cancer, including eligibility criteria, treatment design, outcomes, study locations, and a study protocol document.SummaryDifference49%

- Check17 days agoChange DetectedThe page remains a 403 Forbidden error screen, with the footer revision identifier changing from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check24 days agoChange DetectedA site-wide NIH notice announces a transition from the term “Artificial Intelligence” to “Super Intelligence” under Executive Order 14434.SummaryDifference1%

- Check31 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.7.2 instead of v3.7.1.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.0 to v3.7.1 on an otherwise unchanged 403 error page.SummaryDifference0.2%

- Check59 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the previous study record content. This blocks access to the study details, sponsor and investigator information, locations, and related data.SummaryDifference18%

Stay in the know with updates to Pembrolizumab+Radiotherapy in Metastatic TNBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Radiotherapy in Metastatic TNBC Clinical Trial page.